Skip to main content

povetacicept

povetacicept: 6 clinical trials tracked.

povetacicept evidence translation

What we can confirm

6 tracked trials

No verified listed developer

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about povetacicept, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence5 indications · 3 study sponsors
Clinical Trials (6)

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With a Long-term Extension of Povetacicept in Adults With Generalized Myasthenia Gravis

NCT07501702·Phase 2·VRTX
Recruiting

Primary endpoint: Percent change in Total Immunoglobulin G (IgG)

InterventionalRandomizedquadruple30 targetStarted 2026-05Completion 2029-0326 sites · Australia, Poland, United Kingdom, United StatesVertex Pharmaceuticals Incorporated

A Phase 2b/3 Adaptive, Randomized, Active-controlled Study Evaluating the Efficacy, Safety, and Tolerability of Povetacicept Versus Calcineurin Inhibitor in the Treatment of Primary Membranous Nephropathy

NCT07204275·Phase 2/Phase 3·VRTX
Recruiting

Primary endpoint: Proportion of Participants with Complete Clinical Remission Definition 1 (CR1)

InterventionalRandomizedquadruple176 targetStarted 2025-09Completion 2028-1250 sites · Australia, Brazil, China, United StatesVertex Pharmaceuticals Incorporated

A Phase 1, Open-label, Randomized, 2-part Study to Evaluate the Relative Bioavailability of Povetacicept Formulations and Bioequivalence of Povetacicept Presentations in Healthy Subjects

NCT07010406·Phase 1·VRTX
Completed

Primary endpoint: Area Under the Concentration Versus Time Curve From the Time of Dosing to 28 Days (AUC0-28d) of Free Povetacicept

InterventionalRandomizedopen136 enrolledStarted 2025-06Completion 2025-082 sites · United StatesVertex Pharmaceuticals Incorporated

A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Povetacicept in Adults With Immunoglobulin A Nephropathy (RAINIER)

NCT06564142·Phase 3·IMNP
Active, not recruiting

Primary endpoint: Change From Baseline in 24-hour Urine Protein to Creatinine Ratio (uPCR) at Week 36

InterventionalRandomizedquadruple605 targetStarted 2024-08Completion 2028-0150 sites · United StatesAlpine Immune Sciences Inc, A Subsidiary of Vertex

Open-Label Study to Assess the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Povetacicept in Subjects With Autoimmune Cytopenias (RUBY-4)

NCT05757570·Phase 1/Phase 2·ALPN
Active, not recruiting

Primary endpoint: Safety and Tolerability as Assessed by Adverse events (AEs) and Serious adverse events (SAEs)

Interventionalopen30 enrolledStarted 2023-07Completion 2026-0744 sites · Australia, Austria, Canada, Germany…Alpine Immune Sciences, Inc.

An Open-Label, Multiple-Ascending Dose Study to Assess the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Different Dose Levels of Povetacicept in Subjects With Autoantibody-Associated Glomerular Diseases (RUBY-3)

NCT05732402·Phase 1/Phase 2·ALPN

Primary endpoint: Part A: Safety as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

Interventionalopen72 targetStarted 2023-03Completion 2028-0330 sites · Australia, Puerto Rico, South Korea, United StatesAlpine Immune Sciences, Inc.